オンカジデモプレイ

Japanese English Japanese English Access Contact Site Map Message from the Director Mission Organization Organization Chart Research Divisions Administrative Divisions Facilities and Equipment Logo Access Links iPS Cell Research Fund Request for Support Financial Report Contact Principal Investigators Publications Research Overview Protocols on iPS Cells Training Programs Material Distribution Non-Profit Organization Profit Organization CiRA IP iPS Cell Stock for Regenerative Medicine Internship Program Life at CiRA Graduate Program For High School Students FAQ What are iPS cells? For patients For researchers Other Questions iPS MASTER The road to iPS cells (Poster) Photo Galleries Videos News Media Gallery CiRA Reporter Learn More Open Position Closed T-CiRA Joint Program Fellowships Altos-CiRA Research Project News & Events News & Events Home　›　News & Events　›　2024　›　Research　›　Predicting real-world SARS-CoV-2 evolution by monitoring mutations of viral isolates from an immunocompromised patient News April 03, 2024 Predicting real-world SARS-CoV-2 evolution by monitoring mutations of viral isolates from an immunocompromised patient Junior Associate Professor Kazuo Takayama (Department of Cell Growth and Differentiation) and a collaborative team of researchers in Japan recently characterized SARS-CoV-2 collected from a persistent COVID-19 patient to identify critical factors responsible for generating new mutant strains. The COVID-19 pandemic, caused by the SARS-CoV-2, was in part due to rapid viral evolution that continuously generated new variants. While multiple factors are known to contribute to the rapid emergence of mutant strains, the principal contributing factors remain unclear. In this study, the researchers collected serum samples and viral isolates from an immunocompromised patient who was persistently infected by the SARS-CoV-2 Omicron variant BF.5 over several months to track its evolution and potentially identify crucial factors responsible for the widespread effects of this respiratory virus. Due to chronic immunosuppression as part of the treatment for eosinophilic fasciitis, the researchers detected only low antibody levels against SARS-CoV-2 in the patient. Conversely, although they detected cytolytic granules in the sera collected from the patient, suggesting that NK (natural killer) and CD8+ T cells were likely functional, the research team concluded that these immune cells alone, without sufficient antibody production by B cells, were incapable of successfully eliminating the virus from the patient. The researchers next analyzed the viral genomes isolated from the swab samples by next-generation sequencing methods. Remarkably, whereas the viral genome mutated at 10 locations between the first and two sampling time points (days 0 and 17), it changed at 27 and 37 locations, respectively, during the second and third intervals between sample collection (days 18-56 and 57-119), suggesting the virus could acquire mutations quicker when left unchecked for more than two months. Utilizing their expertise in organoid technology, the researchers examined the viruses' replicative capacity and their effects on host cells by infecting human iPS cell-derived lung organoids with each viral isolate. They detected similar viral gene expression and production levels across isolates, demonstrating that infectivity was generally unaltered during the entire course of a persistent SARS-CoV-2 infection. In addition, the researchers examined the sensitivity to the antiviral drug, remdesivir, and anti-spike protein antibody therapy, sotrovimab, using lung organoids. All viral isolates showed high susceptibility to remdesivir treatment but were largely resistant to the antibody therapy, as they all contained spike protein mutations (G339D or R346T) known to render them resistant to sotrovimab. These findings indicate that infectivity and sensitivity to antiviral treatments remained mostly unchanged despite acquiring multiple mutations during the persistent infection. To determine whether studying the viral isolates from a patient suffering from persistent SARS-CoV-2 infection can help predict viral evolution, the researchers focused on the S protein amino acid sequence and performed comparative phylogenetic analysis with emergent SARS-CoV-2 strains arising in the real world. Notably, several mutations (D574N, S975N, S1003I, and A1174V), relatively rare before the appearance of BF.5, were acquired during persistent infection, indicating that they may be more likely to emerge from the BF.5 strain. The research team thus tested this idea by examining the frequency of these mutations in strains appearing after the BF.5 strain. Remarkably, the D574N and S1003I mutations were detected in greater than 1% of descendant strains emerging from BA.5 (BA.5.24, BA.5.2.36, CG.1, BF.7.26, and BQ.1.1.21), thus demonstrating the potential and real-world implication of analyzing viral evolution in persistently infected patients. In summary, the study illustrates the potential of studying how viruses change over time in patients with persistent infections as a parallel to predict how they may evolve in the real world. However, it is crucial to note that additional persistently infected patients must be included to determine the general applicability of such findings because individual differences could potentially skew viral evolution. Paper Details Journal: iScience Title: Longitudinal analysis of genomic mutations in SARS-CoV-2 isolates from persistent COVID-19 patient Authors: Hiroki Futatsusako1, Rina Hashimoto1, Masaki Yamamoto2, Jumpei Ito3, Yasufumi Matsumura2, Hajime Yoshifuji4, Kotaro Shirakawa5, Akifumi Takaori-Kondo5, Genotype to Phenotype Japan (G2P-Japan) Consortium, Kei Sato3, Miki Nagao2,*, Kazuo Takayama1,6,* Author Affiliations: Center for iPS Cell Research and Application (CiRA), Kyoto University Department of Clinical Laboratory Medicine, Graduate School of Medicine, Kyoto University The Institute of Medical Science, The University of Tokyo Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University AMED-CREST, Japan Agency for Medical Research and Development (AMED) doi: 10.1016/j.isci.2024.109597 News CiRA Reporter Learn More Media Gallery About CiRA Message from the Director Mission Organization Facilities and Equipment Logo Access iPS Cell Research Fund Links Contact Research Activities Principal Investigators Publications Research Overview Protocols on iPS Cells Training Programs Material Distribution CiRA IP iPS Stock Cells for Regenerative Medicine Education & Career Internship Program Graduate Program For High school Students Life at CiRA For the Public FAQ iPS MASTER The road to iPS cells Videos News & Events News CiRA Reporter Learn More Media Gallery Jobs Open Positions Closed T-CiRA Altos-CiRA Fellowships Access　|　Contact　|　Site Map Site Policy - Privacy Policy Copyright © Center for iPS Cell Research and Application, Kyoto University. All rights reserved. About CiRA Research Activities Education & Career For the Public News & Events Jobs Access iPS Cell Research Fund Contact